Can a Dual-Action drug combo outsmart advanced liver cancer?
NCT ID NCT07749859
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether combining an experimental immunotherapy (SHR-1701) with a targeted therapy (apatinib) can shrink tumors in people with advanced liver cancer that has progressed after initial treatment. About 80 adults with unresectable or metastatic hepatocellular carcinoma will receive the combination intravenously and orally every three weeks. The main goal is to see how many patients achieve a significant tumor response, while also monitoring safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Retlirafusp alfa (SHR-1701) injection combined with apatinib tablets
- What this could lead to
- If successful, this combination could offer a new second-line treatment option for people with advanced liver cancer who have already tried targeted and immune therapies.
- What could go wrong
- This is an early-phase, exploratory study with a modest number of participants. The treatment may not shrink tumors in enough patients, and side effects could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Langfang, Hebei, 065000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.